Nucleoid as an Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma
The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).
Hepatocellular Carcinoma|Liver Cancer
PROCEDURE: RFA|DRUG: lamivudine or entecavir
Overall survivals, 3, 5-years
Recurrence rates, 3, 5-years
The purpose of the investigators' study is to prospectively evaluate whether nucleoid antiviral therapy will improve the outcome of radiofrequency ablation for hepatocellular carcinoma (HCC).